Receptor Tyrosine Kinase-Mediated Angiogenesis
Receptor Tyrosine Kinase-Mediated Angiogenesis
复制标题
DOI：
10.1101/cshperspect.a009183
复制
发表时间：
2013-09-01
影响因子：
7.2
通讯作者：
Alitalo, Kari
中科院分区：
文献类型：
--
作者：
Jeltsch, Michael;Leppanen, Veli-Matti;Alitalo, Kari
内皮细胞是构成血管内层的基本细胞类型。两个受体酪氨酸激酶（rtk）家族几乎完全是内皮细胞特异性的：血管内皮生长因子（VEGF）受体（VEGFR1-3）和Tie受体（Tie1和Tie2）。两者都是胚胎发育过程中控制血液和淋巴管生成的关键因素。由于新血液和淋巴管的生长（或缺乏）是许多疾病的中心因素，VEGF和Tie受体为各种疾病提供了有吸引力的治疗靶点。事实上，针对这些RTK信号通路的几种药物已经上市，而许多药物还处于临床试验阶段。在这里，我们回顾了VEGFR和Tie家族，它们在发育性和病理性血管生成中的作用，以及针对它们阻断或增强血管生成和淋巴管生成的不同可能性。
The endothelial cell is the essential cell type forming the inner layer of the vasculature. Two families of receptor tyrosine kinases (RTKs) are almost completely endothelial cell specific: the vascular endothelial growth factor (VEGF) receptors (VEGFR1-3) and the Tie receptors (Tie1 and Tie2). Both are key players governing the generation of blood and lymphatic vessels during embryonic development. Because the growth of new blood and lymphatic vessels (or the lack thereof) is a central element in many diseases, the VEGF and the Tie receptors provide attractive therapeutic targets in various diseases. Indeed, several drugs directed to these RTK signaling pathways are already on the market, whereas many are in clinical trials. Here we review the VEGFR and Tie families, their involvement in developmental and pathological angiogenesis, and the different possibilities for targeting them to either block or enhance angiogenesis and lymphangiogenesis.